RxDoctor Payments DataLook up a doctor →

Russell Neibaur, MD

Internal Medicine · Henderson, NVNPI 1093788051

Payments from drug & device makers

$15,122in general payments, 2019–2025

Across 801 payments — averaging $18.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$2K
  • Amgen$1K
  • AbbVie$1K
  • GSK$1K
  • Regeneron Healthcare Solutions, Inc.$1K
  • Novo Nordisk$862
  • plus $8K from 54 others

What the payments were for

  • Food & beverage$15,110100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pfizer106$1,586
Amgen(2 entities)62$1,323
AbbVie(2 entities)68$1,274
GSK60$1,235
Regeneron Healthcare Solutions, Inc.35$1,031
Novo Nordisk50$862
AstraZeneca40$855
Boehringer Ingelheim44$740
Takeda Pharmaceuticals U.S.A., Inc.30$554
Novartis23$484
Antares Pharma, Inc.25$364
Merck19$334
Bayer20$333
Lilly USA, LLC25$320
Otsuka America Pharmaceutical, Inc.12$261
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC16$238
Astellas Pharma US Inc10$206
Sanofi-aventis U.S. LLC12$202
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)9$174
Pacira Therapeutics, Inc.8$169
Intra-sana Laboratories3$154
Axsome Therapeutics, Inc.6$151
Zimmer Biomet1$137
Eisai Inc.6$134
Radius Health, Inc.6$125
Biohaven Pharmaceuticals, Inc.8$121
Esperion Therapeutics, Inc.5$109
Amarin Pharma, Inc.6$109
Idorsia Pharmaceuticals US Inc6$99
Upsher-smith Laboratories LLC5$92
Arbor Pharmaceuticals, Inc.6$83
Currax Pharmaceuticals LLC5$80
Amneal Pharmaceuticals LLC5$78
Biohaven Pharmaceutical Holding Company Ltd.4$78
Ironwood Pharmaceuticals, Inc5$78
Sanofi3$65
Mylan Specialty L.p.2$64
Halozyme Inc3$59
Johnson & Johnson(2 entities)4$57
Shire North American Group Inc4$55
Phathom Pharmaceuticals, Inc.2$48
Sumitomo Pharma America, Inc.2$42
Kowa Pharmaceuticals America, Inc.3$42
Exact Sciences2$37
Circassia Inc.3$36
UCB, Inc.1$36
IBSA Pharma Inc.2$35
Genentech USA, Inc.2$34
Acerus Pharmaceuticals Corporation1$33
Lundbeck LLC2$33
Abbott1$29
GE HealthCare1$26
Insmed, Inc.1$26
Vanda Pharmaceuticals Inc.1$24
Neuronetics, Inc.1$22
Sun Pharmaceutical Industries Inc.1$21
Kyowa Kirin, Inc.1$20
Amryt Pharma Holdings Ltd1$19
Teva Pharmaceuticals USA, Inc.1$16
Paratek Pharmaceuticals, Inc.1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,122 in reported general payments places this provider in the 95th percentile of 1,071 internal medicine providers in Nevada.

See all internal medicine providers in Nevada

Medicare billing

Part B allowed, 2024
$282,274
Medicare patients
289
Services billed
17,876

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide193$243,649
EliquisApixaban75$64,062
XareltoRivaroxaban45$46,633
Repatha SureclickEvolocumab32$40,880
JardianceEmpagliflozin41$40,750
OzempicSemaglutide37$35,684
Trelegy ElliptaFluticasone/Umeclidin/Vilanter33$30,447
EntrestoSacubitril/Valsartan22$29,035
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog22$10,197
ShingrixVaricella-Zoster Ge/As01b/Pf45$10,131
TrintellixVortioxetine Hydrobromide13$8,014
AbrysvoRsv Vacc, Pref A And Pref B/Pf24$7,715
XyostedTestosterone Enanthate12$6,627
SynthroidLevothyroxine Sodium38$3,755
Nebivolol Hcl49$3,003

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$320$243,649193 claims
PfizerEliquis, Abrysvo, Paxlovid$1,586$73,206116 claims
Johnson & JohnsonXarelto$57$46,63345 claims
Boehringer IngelheimJardiance$740$40,75041 claims
GSKTrelegy Ellipta, Shingrix$1,235$40,57878 claims
Novo NordiskOzempic$862$35,68437 claims
NovartisEntresto$484$29,03522 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$554$8,01413 claims
Antares Pharma, Inc.Xyosted$364$6,62712 claims
AbbVieSynthroid$1,274$3,75538 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$78$2,032277 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,071 internal medicine providers in Nevada.

Other internal medicine in Henderson

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →